HIV整合酶抑制剂
| 英文名 | Dolutegravir (GSK1349572) | CAS号 | 1051375-16-6 |
| 试剂别名 |
GSK1349572;(4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide;Dolutegravir;Dolutegravir (GSK1349572);Dolutegravir-D5;GSK-1349572;Tivicay;(4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;Dolutegravi;S/GSK1349572;Dolutegravir API;Dolutegravir, >=98%;Dolutegravir free acid;GSK1349572(dolutegravir);S/GSK1349572 (GSK1349572)
|
分子式 | C20H19F2N3O5 |
| 产品编号 | APEA4074 | 分子量 | 419.38 |
| MDL号 |
| 产品名称： | HIV整合酶抑制剂 |
| 英文名称： | Dolutegravir (GSK1349572) |
| 英文别名： | GSK1349572;(4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazine-9-carboxamide;Dolutegravir;Dolutegravir (GSK1349572);Dolutegravir-D5;GSK-1349572;Tivicay;(4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;Dolutegravi;S/GSK1349572;Dolutegravir API;Dolutegravir, >=98%;Dolutegravir free acid;GSK1349572(dolutegravir);S/GSK1349572 (GSK1349572) |
| 中文别名： | 度鲁特韦 |
| CAS No.： | 1051375-16-6 |
| 分子式： | C20H19F2N3O5 |
| 分子量： | 419.38 |
| 危险品级别： | |
| HS符号： | |
| 危害声明： |
